GPC3-Targeted PET/CT in Hepatocellular Carcinoma
Glypian-3 (GPC3)- Targeted PET Imaging in Hepatocellular Carcinoma
1 other identifier
interventional
40
1 country
1
Brief Summary
The objective of the study is to evaluate the diagnostic value of GPC3-targeted PET/CT in patients with suspected or histologically/clinically confirmed hepatocellular carcinoma, and to compare with 18F-FDG PET/CT.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started May 2026
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2026
CompletedFirst Submitted
Initial submission to the registry
June 8, 2026
CompletedFirst Posted
Study publicly available on registry
July 1, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 31, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
May 31, 2028
July 1, 2026
May 1, 2026
2.1 years
June 8, 2026
June 25, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Diagnostic efficacy
The sensitivity, specificity, and accuracy of 18F-FDG PET/CT and GPC3-targeted PET/CT were calculated and compared to evaluate the diagnostic accuracy.
1 year
Secondary Outcomes (1)
Gastric SUVmax Stratified by Gastric Filling Status
1 day
Study Arms (1)
GPC3-targeted PET/CT
EXPERIMENTALEach subject receives a single intravenous injection of GPC3-targeted probe and undergoes PET/CT imaging within the specified time.
Interventions
Participants will receive a single intravenous injection of 18F-FDG and 68Ga-GPC3, and undergo PET/CT imaging within the specified time.
Eligibility Criteria
You may qualify if:
- Adult patients (aged 18 years or older);
- Patients with suspected, newly diagnosed, or previously treated hepatocellular carcinoma(supporting evidence may include imaging findings and pathology report);
- Patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.
- Estimated life expectancy of more than 3 months, as assessed by the investigator, and ability to comply with study procedures and scheduled visits;
You may not qualify if:
- The inability or unwillingness of the research participant or legal representative to provide written informed consent.
- Inability to complete PET/CT imaging.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, 361000, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 8, 2026
First Posted
July 1, 2026
Study Start
May 1, 2026
Primary Completion (Estimated)
May 31, 2028
Study Completion (Estimated)
May 31, 2028
Last Updated
July 1, 2026
Record last verified: 2026-05
Data Sharing
- IPD Sharing
- Will not share